Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab

Brendan K Bowens; Eva Chou; David P LaChance; James R Huynh; Patrick Voorhees; Thanh C Do; Mohamed K M Shakir; Thanh D Hoang

doi:10.1002/ccr3.6621

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab

Clin Case Rep. 2022 Nov 19;10(11):e6621. doi: 10.1002/ccr3.6621. eCollection 2022 Nov.

Authors

Brendan K Bowens¹, Eva Chou², David P LaChance^{1

3}, James R Huynh¹, Patrick Voorhees⁴, Thanh C Do³, Mohamed K M Shakir^{3

5}, Thanh D Hoang^{3

5}

Affiliations

¹ Department of Medicine Dwight D. Eisenhower Army Medical Center Augusta Georgia USA.
² Department of Ophthalmology Walter Reed National Military Medical Center Bethesda Maryland USA.
³ Division of Endocrinology, Department of Medicine Uniformed Service University of the Health Sciences Bethesda Maryland USA.
⁴ Department of Pathology Walter Reed National Military Medical Center Bethesda Maryland USA.
⁵ Division of Endocrinology, Department of Medicine Walter Reed National Military Medical Center Bethesda Maryland USA.

Abstract

We report a 51-year-old woman with thyroid eye disease and biopsy-proven pretibial myxedema that was subsequently treated with teprotumumab with improvement.

Keywords: Graves' disease; pretibial myxedema; teprotumumab; thyroid eye disease.

Published 2022. This article is a U.S. Government work and is in the public domain in the USA. Clinical Case Reports published by John Wiley & Sons Ltd.

Publication types

Case Reports